MX2013008543A - Sistema de administracion transdermica de farmacos y metodo para usar el mismo. - Google Patents
Sistema de administracion transdermica de farmacos y metodo para usar el mismo.Info
- Publication number
- MX2013008543A MX2013008543A MX2013008543A MX2013008543A MX2013008543A MX 2013008543 A MX2013008543 A MX 2013008543A MX 2013008543 A MX2013008543 A MX 2013008543A MX 2013008543 A MX2013008543 A MX 2013008543A MX 2013008543 A MX2013008543 A MX 2013008543A
- Authority
- MX
- Mexico
- Prior art keywords
- delivery system
- drug delivery
- transdermal drug
- steroid
- adhesive layer
- Prior art date
Links
- 238000013271 transdermal drug delivery Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 abstract 3
- 239000010410 layer Substances 0.000 abstract 3
- 150000003431 steroids Chemical class 0.000 abstract 3
- 210000000744 eyelid Anatomy 0.000 abstract 2
- 241001608562 Chalazion Species 0.000 abstract 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229960003099 amcinonide Drugs 0.000 abstract 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 abstract 1
- 229960001102 betamethasone dipropionate Drugs 0.000 abstract 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 abstract 1
- 208000010217 blepharitis Diseases 0.000 abstract 1
- 229960004703 clobetasol propionate Drugs 0.000 abstract 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 abstract 1
- 229960003744 loteprednol etabonate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un sistema de administración transdérmica de fármacos que comprende un esteroide como agente activo, en donde el esteroide puede ser propionato de clobetasol, dipropionato de betametasona, amcinonida o etabonato de loteprednol. El sistema de administración transdérmica de fármacos también comprende una capa de adhesivo sensible a la presión y un soporte, en donde el esteroide está presente en la capa de adhesivo sensible a la presión, y en donde la capa de adhesivo sensible a la presión se proporciona en un soporte. El sistema de administración transdérmica de fármacos se puede aplicar sobre el párpado de un paciente en necesidad del mismo, con el fin de tratar una enfermedad del párpado, tal como chalazión, blefaritis o disfunción de las glándulas de Meibomio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/164,037 US8900626B2 (en) | 2011-06-20 | 2011-06-20 | Transdermal drug delivery system and method of using the same |
| PCT/US2012/043126 WO2012177626A1 (en) | 2011-06-20 | 2012-06-19 | Transdermal drug delivery system and method of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013008543A true MX2013008543A (es) | 2013-08-12 |
| MX347195B MX347195B (es) | 2017-04-19 |
Family
ID=47353860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013008543A MX347195B (es) | 2011-06-20 | 2012-06-19 | Sistema de administración transdérmica de fármacos y método para usar el mismo. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8900626B2 (es) |
| EP (1) | EP2720748B1 (es) |
| JP (2) | JP6296977B2 (es) |
| KR (2) | KR20190026963A (es) |
| CN (1) | CN103429295B (es) |
| CA (1) | CA2831095C (es) |
| ES (1) | ES2627514T3 (es) |
| MX (1) | MX347195B (es) |
| WO (1) | WO2012177626A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1591110B1 (en) * | 2003-01-22 | 2015-03-18 | Senju Pharmaceutical Co., Ltd. | Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye |
| US8915253B2 (en) | 2005-07-18 | 2014-12-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
| US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
| WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
| US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
| US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
| US20090043365A1 (en) | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
| US8950405B2 (en) * | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
| US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
| US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
| US9211397B2 (en) * | 2012-12-19 | 2015-12-15 | Senju Usa, Inc. | Patch for treatment of eyelid disease containing clobetasol |
| US9820954B2 (en) | 2015-08-19 | 2017-11-21 | Jenivision Inc. | Quantitative peri-orbital application of ophthalmology drugs |
| US12011388B2 (en) | 2016-03-01 | 2024-06-18 | The Hilsinger Company Parent, Llc | Therapeutic thermal compress with phase-change material |
| US12029681B2 (en) | 2016-03-01 | 2024-07-09 | The Hilsinger Company Parent, Llc | Therapeutic eye mask system |
| US12156831B2 (en) | 2016-03-01 | 2024-12-03 | The Hilsinger Company Parent, Llc | Therapeutic eye compress system |
| US20190167568A1 (en) * | 2016-06-29 | 2019-06-06 | Senju Usa, Inc. | Transdermal Drug Delivery System and Method for Using Same |
| USD871598S1 (en) | 2016-11-30 | 2019-12-31 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
| USD844795S1 (en) | 2016-11-30 | 2019-04-02 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
| BR112020008046A2 (pt) | 2017-11-21 | 2020-10-27 | Axerovision, Inc. | composições e métodos de uso para tratamento de inflamação anormal em glândulas secretoras perioculares ou na superfície ocular |
| US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| JP7332602B2 (ja) * | 2017-12-28 | 2023-08-23 | センジュ ユーエスエー、インコーポレイテッド | 経皮薬物送達システムおよびその使用方法 |
| CA3092966A1 (en) | 2018-03-02 | 2019-09-06 | The Schepens Eye Research Institute | System and method for treating meibomian gland dysfunction |
| WO2022010864A1 (en) * | 2020-07-06 | 2022-01-13 | Kindeva Drug Delivery L.P. | Drug delivery device for delivery of clobetasol propionate |
| EP4247367A4 (en) | 2020-11-23 | 2024-10-16 | Sight Sciences, Inc. | Formulations and methods for treating conditions of the eye |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1047519A (en) | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª‡,21-diesters of 11,17,21-trihydroxy steroid compounds |
| GB1253831A (en) | 1968-01-19 | 1971-11-17 | Glaxo Lab Ltd | 9alpha,21-DIHALOPREGNANE COMPOUNDS |
| ZA744259B (en) | 1973-08-17 | 1975-06-25 | American Cyanamid Co | Topical steroid |
| US4666441A (en) | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
| US4954343A (en) * | 1986-03-29 | 1990-09-04 | Nitto Electric Industrial Co., Ltd. | Dermal pharmaceutical preparations |
| WO1989003390A1 (en) | 1987-10-13 | 1989-04-20 | Bodor Nicholas S | Soft steroids having anti-inflammatory activity |
| ZA966579B (en) * | 1995-08-04 | 1998-02-02 | Wakamoto Pharma Co Ltd | O/W emulsion composition for eye drops. |
| JP2001009985A (ja) * | 1999-07-02 | 2001-01-16 | Hisamitsu Pharmaceut Co Inc | 貼付剤用包装袋及び包装貼付剤 |
| WO2001026648A1 (en) | 1999-10-13 | 2001-04-19 | Senju Pharmaceutical Co., Ltd. | Ophthalmic adhesive preparations for percutaneous absorption |
| US20050058695A1 (en) * | 2002-05-30 | 2005-03-17 | Watson Pharmaccuticals, Inc. | Norethindrone sustained release formulations and methods associated therewith |
| EP1591110B1 (en) * | 2003-01-22 | 2015-03-18 | Senju Pharmaceutical Co., Ltd. | Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye |
| US20050245497A1 (en) * | 2004-04-08 | 2005-11-03 | Penfold Philip L | Treatment of ophthalmic conditions |
| US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
| US20070053964A1 (en) | 2004-05-21 | 2007-03-08 | Akiharu Isowaki | Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
| KR20070104912A (ko) | 2005-02-17 | 2007-10-29 | 센주 세이야꾸 가부시키가이샤 | 안과용 고형 외용약제 |
| JP2008538754A (ja) * | 2005-04-11 | 2008-11-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 薬剤を含んだ所定のレイヤパターンを有する複層構造体 |
| JP5315051B2 (ja) | 2005-07-08 | 2013-10-16 | 千寿製薬株式会社 | オロパタジンを含む眼科用経皮吸収型製剤 |
| US20090143359A1 (en) | 2005-07-08 | 2009-06-04 | Akiharu Isowaki | Percutaneously Absorptive Ophthalmic Preparation Comprising Epinastine |
| JPWO2007013661A1 (ja) | 2005-07-26 | 2009-02-12 | 千寿製薬株式会社 | 眼科用経皮吸収型製剤 |
| KR20090042956A (ko) | 2006-08-28 | 2009-05-04 | 센주 세이야꾸 가부시키가이샤 | 안과 경피 흡수형 제제 |
| JP5485135B2 (ja) | 2008-02-27 | 2014-05-07 | 久光製薬株式会社 | 貼付製剤 |
| US20090297590A1 (en) | 2008-05-30 | 2009-12-03 | Masahiro Yamaji | Ketotifen transdermal drug delivery systems and methods for treating ophthalmic disease |
| AU2009261285B2 (en) * | 2008-06-19 | 2012-12-13 | Fuso Pharmaceutical Industries, Ltd | Peptide derivative and composition for promoting tear secretion comprising the same |
| US10201548B2 (en) | 2009-03-06 | 2019-02-12 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| TW201039815A (en) * | 2009-04-13 | 2010-11-16 | Resolvyx Pharmaceuticals Inc | Compositions and methods for the treatment of inflammation |
| TWI445708B (zh) * | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| ES2752008T3 (es) | 2009-10-30 | 2020-04-02 | Intratus Inc | Métodos y composiciones para la liberación sostenida de fármacos |
| JP2013527559A (ja) * | 2010-03-31 | 2013-06-27 | キーケルト アーゲー | 自動車用のアクチュエータおよび施錠装置および方法 |
| EP2505618A1 (en) * | 2011-04-01 | 2012-10-03 | Fábrica Nacional De Moneda Y Timbre | Use of electromagnetic wave absorbing markers for the aunthentication of security documents |
-
2011
- 2011-06-20 US US13/164,037 patent/US8900626B2/en not_active Expired - Fee Related
-
2012
- 2012-06-19 CN CN201280006627.7A patent/CN103429295B/zh not_active Expired - Fee Related
- 2012-06-19 JP JP2014517085A patent/JP6296977B2/ja not_active Expired - Fee Related
- 2012-06-19 ES ES12802854.5T patent/ES2627514T3/es active Active
- 2012-06-19 CA CA2831095A patent/CA2831095C/en not_active Expired - Fee Related
- 2012-06-19 MX MX2013008543A patent/MX347195B/es active IP Right Grant
- 2012-06-19 WO PCT/US2012/043126 patent/WO2012177626A1/en not_active Ceased
- 2012-06-19 EP EP12802854.5A patent/EP2720748B1/en not_active Not-in-force
- 2012-06-19 KR KR1020197006444A patent/KR20190026963A/ko not_active Ceased
- 2012-06-19 KR KR1020137025876A patent/KR102107977B1/ko not_active Expired - Fee Related
-
2016
- 2016-10-14 JP JP2016202990A patent/JP2017048201A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6296977B2 (ja) | 2018-03-20 |
| WO2012177626A1 (en) | 2012-12-27 |
| US8900626B2 (en) | 2014-12-02 |
| MX347195B (es) | 2017-04-19 |
| JP2014519955A (ja) | 2014-08-21 |
| CN103429295B (zh) | 2017-03-29 |
| CA2831095C (en) | 2015-12-01 |
| CN103429295A (zh) | 2013-12-04 |
| US20120321673A1 (en) | 2012-12-20 |
| KR20140019790A (ko) | 2014-02-17 |
| ES2627514T3 (es) | 2017-07-28 |
| EP2720748B1 (en) | 2017-05-17 |
| KR20190026963A (ko) | 2019-03-13 |
| CA2831095A1 (en) | 2012-12-27 |
| EP2720748A1 (en) | 2014-04-23 |
| EP2720748A4 (en) | 2014-11-26 |
| JP2017048201A (ja) | 2017-03-09 |
| KR102107977B1 (ko) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX347195B (es) | Sistema de administración transdérmica de fármacos y método para usar el mismo. | |
| JP2014519955A5 (es) | ||
| IN2012DN01225A (es) | ||
| MX381164B (es) | Composiciones tópicas de corticosteroides. | |
| MY161021A (en) | Controlled release corticosteroid and methods for the treatment of otic disorders | |
| SG194155A1 (en) | Multilayer thin film drug delivery device and methods of making and using the same | |
| BRPI0713257B8 (pt) | sistema terapêutico transdérmico para a aplicação de norelgestromina | |
| PH12014501351A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| ATE496617T1 (de) | Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern | |
| UA109785C2 (uk) | Композиція фармацевтичного аерозолю, яка включає аналог вітаміну d і кортикостероїд | |
| SG10201907588XA (en) | Androgen Receptor Modulators And Uses Thereof | |
| MY183873A (en) | Transdermal therapeutic system for application of an agent | |
| CA3010829A1 (en) | Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof | |
| BR112014018439A8 (pt) | Terapias de reposição de hormônio transdérmica | |
| IN2014DN09817A (es) | ||
| MY182222A (en) | Pharmaceutical compositions and methods of use of 4-pregenen- 11?-17-21-triol-3,20-dione derivatives | |
| MX2016008138A (es) | Sistema para el suministro transdermico de ingredientes activos. | |
| EP3513789A3 (en) | Prophylactic and therapeutic agents for fgfr3 diseases | |
| AU2013330679A8 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| BR112012029697A2 (pt) | polissacarídeo da semente de tamarindo para uso no tratamento de doenças inflamatórias | |
| WO2009076413A3 (en) | Methods, devices and compositions for controlled drug delivery to injured myocardium | |
| PH12014501573A1 (en) | Topical pharmaceutical compositions comprising bexarotene and a corticosteroids | |
| BR112022012111A2 (pt) | Sistema terapêutico transdérmico contendo agomelatina | |
| WO2014123543A3 (en) | Skin permeating and cell entering (space) peptides and methods of use therefor | |
| WO2012111996A3 (ko) | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |